![Logo](/assets/logo-d3f1fdf60522f0983e71f9fcc720cb7da5b55c0b748ed5bded3d2fbf81387bf0.png)
PMC:7441788 / 1068-1699
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T13 | 212-220 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T14 | 307-315 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T15 | 422-430 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T16 | 505-513 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T6 | 148-149 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T13 | 111-113 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T14 | 150-159 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T15 | 284-286 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T16 | 398-400 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T17 | 480-491 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
T18 | 495-497 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T10 | 111-113 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T11 | 150-159 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T12 | 284-286 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T13 | 398-400 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
T14 | 495-497 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T11 | 212-220 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T12 | 307-315 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T13 | 422-430 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T14 | 505-513 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 61-221 | Sentence | denotes | However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. |
T15 | 222-325 | Sentence | denotes | Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. |
T16 | 326-617 | Sentence | denotes | Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies. |
T17 | 619-621 | Sentence | denotes | 1. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
46 | 198-206 | Species | denotes | patients | Tax:9606 |
47 | 316-324 | Species | denotes | patients | Tax:9606 |
55 | 111-117 | Chemical | denotes | CQ/HCQ | |
56 | 150-159 | Chemical | denotes | macrolide | MESH:D018942 |
57 | 284-286 | Chemical | denotes | CQ | MESH:D002738 |
58 | 287-290 | Chemical | denotes | HCQ | MESH:D006886 |
59 | 398-400 | Chemical | denotes | CQ | MESH:D002738 |
60 | 401-404 | Chemical | denotes | HCQ | MESH:D006886 |
61 | 495-497 | Chemical | denotes | CQ | MESH:D002738 |
62 | 498-501 | Chemical | denotes | HCQ | MESH:D006886 |
70 | 212-220 | Disease | denotes | COVID-19 | MESH:C000657245 |
71 | 307-315 | Disease | denotes | COVID-19 | MESH:C000657245 |
72 | 422-430 | Disease | denotes | COVID-19 | MESH:C000657245 |
73 | 505-513 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 5-12 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T11 | 212-220 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T12 | 307-315 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T13 | 422-430 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T14 | 505-513 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sample-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 249-270 | Phenotype | denotes | prolonged QT interval | http://purl.obolibrary.org/obo/HP_0001657 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
46 | 198-206 | Species | denotes | patients | Tax:9606 |
47 | 316-324 | Species | denotes | patients | Tax:9606 |
55 | 111-117 | Chemical | denotes | CQ/HCQ | |
56 | 150-159 | Chemical | denotes | macrolide | MESH:D018942 |
57 | 284-286 | Chemical | denotes | CQ | MESH:D002738 |
58 | 287-290 | Chemical | denotes | HCQ | MESH:D006886 |
59 | 398-400 | Chemical | denotes | CQ | MESH:D002738 |
60 | 401-404 | Chemical | denotes | HCQ | MESH:D006886 |
61 | 495-497 | Chemical | denotes | CQ | MESH:D002738 |
62 | 498-501 | Chemical | denotes | HCQ | MESH:D006886 |
70 | 212-220 | Disease | denotes | COVID-19 | MESH:C000657245 |
71 | 307-315 | Disease | denotes | COVID-19 | MESH:C000657245 |
72 | 422-430 | Disease | denotes | COVID-19 | MESH:C000657245 |
73 | 505-513 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 61-221 | Sentence | denotes | However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. |
T15 | 222-325 | Sentence | denotes | Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. |
T16 | 326-617 | Sentence | denotes | Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies. |
T17 | 619-621 | Sentence | denotes | 1. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 249-270 | Phenotype | denotes | prolonged QT interval | http://purl.obolibrary.org/obo/HP_0001657 |